Skip to main content

Advertisement

SpringerLink
Log in

Update on the Prevention of Type 2 Diabetes

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetes has emerged as the modern day epidemic that is currently affecting over 220 million people worldwide and claiming at least 1.1 million lives in 2005 alone. The rise in diabetes is largely attributed to the epidemic of obesity together with sedentary lifestyle as well as unhealthy dietary habits. Despite evidence that glycemic control as well as control of other cardiovascular disease (CVD) risk factors such as hypertension and dyslipidemia decreases morbidity and mortality in the diabetic population, control of glycemia and other CVD risk factors remains largely suboptimal making the concept of prevention of diabetes very appealing to control CVD risk, especially that such a risk is already increased in people in the prediabetic stage. Several large controlled trials have been completed testing various options for diabetes prevention. In this paper we present an update on prevention of type 2 diabetes highlighting the major recent trials completed to date in this very important area of investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ACT NOW:

Actos Now for Prevention of Diabetes

ALLHAT:

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

BIP:

Bezafibrate Infarction Prevention

CANOE:

Canadian Normoglycemia Outcomes Evaluation

CAPP:

Captopril Prevention Project

DPP:

Diabetes Prevention Program

DREAM:

Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medications

HOPE:

Heart Outcomes Prevention Evaluation

LIFE:

Losartan Intervention for Endpoint Reduction in Hypertension study

NAVIGATOR:

Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research

SOS:

Swedish Obese Subjects

STOP-NIDDM:

Study to Prevent Non-Insulin Dependent Diabetes Mellitus

TRIPOD:

Troglitazone in Prevention of Diabetes

WOSCOPS:

West of Scotland Coronary Prevention Study

XENDOS:

Xenical in the Prevention of Diabetes in Obese Subjects.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. World Health Organization (WHO). Fact Sheet No 312 November 2009. Available at http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed on September 30, 2010.

  2. 2007 National Diabetes Fact Sheet available at http://www.cdc.gov/nchs/fastats/diabetes.htm. Accessed on September 30, 2010.

  3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004. 27:1047–1053

    Article  PubMed  Google Scholar 

  4. Farag A, Karam J, Nicasio J, McFarlane SI. Prevention of type 2 Diabetes: An Update. Current Diabetes Reports 2007. 7:200–207

    Article  CAS  PubMed  Google Scholar 

  5. Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 2005. 366(9493):1279–1289

    Article  CAS  PubMed  Google Scholar 

  6. McFarlane SI, Jacober SJ, Winer N, et al: Control of Cardiovascular Risk factors in patients with diabetes and hypertension of urban academic medical centers. Diabetes Care 2002. 25:718–723.

    Article  PubMed  Google Scholar 

  7. McFarlane SI, Sowers JR: Gender disparities in the control of cardiovascular risk factors in people with diabetes. J Clin Hypertens (Greenwich) 2005.7:383–385

    Article  Google Scholar 

  8. Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors 2001, JAMA 2003, 289(1):76–79.

    Article  PubMed  Google Scholar 

  9. Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37: 1053–1059.

    CAS  PubMed  Google Scholar 

  10. Hussain A, Claussen B, Ramachandran A, et al. Prevention of type 2 diabetes: A review. Diab. Res. Clin. Pract 2007, 76 (3): 317–326.

    Article  CAS  Google Scholar 

  11. •• American Diabetes Association: Standards of Medical Care in Diabetes – 2010. Diabetes Care 2010. 33:S11–61. This paper summarizes the most recent American Diabetes Association (ADA) guidelines of diagnosing diabetes and prediabetes and includes a section on identifying and managing the population at risk of developing diabetes.

  12. Cdc.gov/diabetes/pubs/general07.htm

  13. •• Nathan DM, Davidson MB, DeFronzo A, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30 (3): 753–758. This ADA statement answers important questions about pathogenesis, natural history, screening, and management of patients with IFG and IGT.

    Article  CAS  PubMed  Google Scholar 

  14. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354(9179):617–621.

    Google Scholar 

  15. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002, 25(7):1129–1134.

    Article  PubMed  Google Scholar 

  16. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.

    Article  CAS  PubMed  Google Scholar 

  17. Lindstrom J, Ilanne-Parikka P, Peltonen N, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368 (9548):1673–1679.

    Article  PubMed  Google Scholar 

  18. Knowler WC, Barrett-Connor E, Fowler, SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  CAS  PubMed  Google Scholar 

  19. • Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009. 374 (9702):1677–1686. This follow-up study of the DPP trial demonstrates a sustained effect of lifestyle changes in preventing diabetes 5 years after discontinuation of the initial trial.

    Article  PubMed  Google Scholar 

  20. Devlin JT: Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992, 15:1690–1693.

    Article  CAS  PubMed  Google Scholar 

  21. Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and Diabetes Study. Diabetes Care 1997, 20:537–544.

    Article  CAS  PubMed  Google Scholar 

  22. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in teh China Da Quing Diabetes Prevention Study; a 20-year follow-up study. Lancet 2008. 371(9626):1783–1789

    Article  PubMed  Google Scholar 

  23. Jeon CY, Lokken RO, Hu FB, et al. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care 2007, 30 (3), 744–752.

    Article  PubMed  Google Scholar 

  24. Hamman RF, Wing PR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29 (9):2102–2107.

    Article  PubMed  Google Scholar 

  25. Kirpichnikov D, McFarlane SI, Sowers J: Metformin: An Update. Ann Intern Med 2002, 137:25–33.

    CAS  PubMed  Google Scholar 

  26. Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a hisotry of Getational Diabetes: Effects of metformin and lifestyle interventions. J Clin Endocrinol Metab.2008.93(12):4774–4779.

    Article  CAS  PubMed  Google Scholar 

  27. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003, 26 (4): 977–980.

  28. Salpeter SR, Buckley MS, Kahn JA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008, 121 (2): 149–157 e2

    Article  CAS  PubMed  Google Scholar 

  29. El_Atat F, Nicasio J, Clarke L, et al.: Beneficial Cardiovascular Effects of Thiazolidinediones. Therapy 2005; 2:113–119

    Article  CAS  Google Scholar 

  30. Buchanon A, Xiang A, Peters R, et al. Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Diabetes 2002, 51:2796–2803.

    Article  Google Scholar 

  31. DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096–1105.

    Article  Google Scholar 

  32. DeFronzo RA, for ACT NOW Study Group. ACTos NOW Study for the prevention of diabetes (ACT NOW) Study. Late breaking abstract at 68th Annual Scientific Session of the American Diabetes Association, 6 june 2008, San Francisco, CA

  33. Zinman B, Harris S,Neuman J. Low dose combination therapy with rosiglitazone and metfomin to prevent type 2 diabetes (CANOE trial): a double blind controlled study. Lancet 2010, 376 :103–11

    Article  CAS  PubMed  Google Scholar 

  34. Chiasson JL, Josse RG, Leiter LA, et al.: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996, 19:1191–1194.

    Article  Google Scholar 

  35. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072–2077.

    Article  CAS  PubMed  Google Scholar 

  36. Van de Laar FA, Lucassen PL, Akkermans RP, et al.: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006, 4:CD005061.

    PubMed  Google Scholar 

  37. Kawamori R, Tajima N, Iwamato Y,et al. Voglibose for prevention of type 2 diabetes mellitus: a randomisd, double-blind trial in japanese individuals with impaired glucose tolerance. Lancet 2009, 373 (9675):1607–1614

    Article  CAS  PubMed  Google Scholar 

  38. Holman RR, Haffner SM, McMurray IJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362 (16):1463–1476

    Article  CAS  PubMed  Google Scholar 

  39. Yusuf S, Gerstein H, Hoogwerf, B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882–1885

    Article  CAS  PubMed  Google Scholar 

  40. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-enzyme-inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial. Lancet 1999, 353: 611–616

    Article  CAS  PubMed  Google Scholar 

  41. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.

    Article  Google Scholar 

  42. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004–1010.

    Article  PubMed  Google Scholar 

  43. Gillespie EL, White CM, Kardas M, et al.: The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28:2261–2266.

    Article  CAS  PubMed  Google Scholar 

  44. The DREAM trial investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551–1561.

    Article  Google Scholar 

  45. McMurray JJ, Holman RR, haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362: 1477

    Article  CAS  PubMed  Google Scholar 

  46. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91: H30-H37

    Article  Google Scholar 

  47. Henriken EJ, Jacob S: Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003, 196: 171–179

    Article  Google Scholar 

  48. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41:127–133.

    Article  CAS  PubMed  Google Scholar 

  49. Scheen A: Prevention of Type 2 Diabetes Mellitus through Inhibition of the Renin-Angiotensin System. Drugs 2004, 64:2537–2565.

    Article  CAS  PubMed  Google Scholar 

  50. Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321–1326.

    Article  CAS  PubMed  Google Scholar 

  51. Torgerson JS, Hauptman J, Boldrin MN, et al.: Xenical in the prevention of diabetes in obese subjects (XENDOS) Study. Diabetes Care 2004, 27: 155–161.

    Article  CAS  PubMed  Google Scholar 

  52. McFarlane SI, Muniyappa R, Francisao R, et al: Clinical Review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87:1451–1458.

    Article  CAS  PubMed  Google Scholar 

  53. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the Development of Diabetes Mellitus: Evidence of a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.

    CAS  PubMed  Google Scholar 

  54. Athyros VG, Tziomalos K, Karagiannis A et al. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother. 2010,11 (12): 1965–1970

    Article  CAS  PubMed  Google Scholar 

  55. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator receptor (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005, 16; 4:14.

    Google Scholar 

  56. Rovellini A, Sommariva D, Branchi A, et al. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res. 1992, 25:237–45.

    Article  CAS  PubMed  Google Scholar 

  57. Tenenbaum A, Motro M, Fisman EZ, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005 Oct, 26:2032–8.

    Article  CAS  PubMed  Google Scholar 

  58. Tenenbaum A, Motro M, Fisman E, et.al: Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for prevention of type 2 Diabetes Mellitus in patients with coronary artery disease. Circulation 2004;109:2197–2202.

    Article  CAS  PubMed  Google Scholar 

  59. Sjostrom L, Lindroos AK, Peltonen M, et al: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004; 351:2683–2693

    Article  Google Scholar 

  60. Sjostrom CD: Surgery as an intervention for obesity. Results from the Swedish Obese Subjects Study. Growth Hormone and IGF Research 2003; 13:S22–S26

    Article  PubMed  Google Scholar 

  61. Pories WJ, Swanson MS, MacDonald KG, et al: Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Annals of Surgery 1995; 222: 339–350.

    Article  CAS  PubMed  Google Scholar 

  62. Long SD, O’Brien K, MacDonald KG Jr, et al.: Weight loss in severely obese subjects prevents the prevention of impaired glucose tolerance test to type II Diabetes. A longitudinal interventional study. Diabetes care 1994, 17: 372–375.

    CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY, 11219, USA

    Jocelyne G. Karam & Samy I. McFarlane

Authors
  1. Jocelyne G. Karam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samy I. McFarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jocelyne G. Karam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karam, J.G., McFarlane, S.I. Update on the Prevention of Type 2 Diabetes. Curr Diab Rep 11, 56–63 (2011). https://doi.org/10.1007/s11892-010-0163-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-010-0163-x

Keywords

Search

Navigation